Table 1.

Clinicopathologic features comparison among patients harboring different genes

	ROS1 (n = 34)	ALK (n = 46)	KRAS (n = 32)	EGFR (n = 50)	wild‐type (n = 42)	P (ROS1 vs. ALK)	P (ROS1 vs. KRAS)	P (ROS1 vs. EGFR)	P (ROS1 vs. wild‐type)
Gender						0.90	0.02	0.32	0.28
Male	16	21	24	29	25
Female	18	25	8	21	17
Age at diagnosis						0.89	0.13	0.67	0.85
<60	19	28	13	32	24
≥60	13	18	19	18	18
Smoking history						0.31	<0.001	0.007	0.0044
Yes	5	11	22	21	19
No	29	35	10	29	23
Histology						0.61	0.44	0.24	0.89
Adenocarcinoma	34	44	30	46	41
Nonadenocarcinoma	0	2	2	4	1
Stage at diagnosis						0.80	0.46	0.99	0.76
I‐IIIA	19	27	15	28	22
IIIB/IV	15	19	17	22	20
Pemetrexed‐based chemotherapy						0.41	0.42	0.48	0.57
First‐line	12	24	19	28	23
Second or third‐line	6	7	4	9	8